Invasive aspergillosis remains a serious opportunistic fungal infection particularly in patients with a reduced
immune defense such as those with hematological malignancies or transplant recipients. The mortality of invasive
infections due to Aspergillus spp. is still high. The main reasons for this are the difficulty in diagnosing of these infections
and the limited efficacy of antifungal agents. There is no optimal therapy for invasive aspergillosis, and therefore many
clinicians have attempted to utilize a combination approach to improve outcomes. The current antifungal classes of drugs
targeting the cell wall and cell membrane may need adjunctive agents focused on separate cellular pathways that can be
used in combination therapy to maximize the efficacy, a valuable alternative to the monotherapy. The endeavor of this
article is to review the literature on combination therapy by using adjunctive agents against Aspergillus spp and assess its
eventual usability in the treatment of invasive aspergillosis.
Keywords: Aspergillus, Aspergillosis, Adjunctive agent, Combination therapy, Monotherapy.
Rights & PermissionsPrintExport
Published on: 04 September, 2012
Page: [1261 - 1272]